Phase I clinical trial of CPI-613 in combination with gemcitabine and nab-paclitaxel in the patients with locally advanced or metastatic pancreatic cancer.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs CPI 613 (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- 23 Nov 2017 New trial record
- 16 Nov 2017 According to a Rafael Pharmaceuticals media release, this study will be in collaboration with Atlantic Health System.